JP3117964B2 - Antitumor substance - Google Patents

Antitumor substance

Info

Publication number
JP3117964B2
JP3117964B2 JP11115335A JP11533599A JP3117964B2 JP 3117964 B2 JP3117964 B2 JP 3117964B2 JP 11115335 A JP11115335 A JP 11115335A JP 11533599 A JP11533599 A JP 11533599A JP 3117964 B2 JP3117964 B2 JP 3117964B2
Authority
JP
Japan
Prior art keywords
substance
tumor
antitumor
tumor cells
tumor cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP11115335A
Other languages
Japanese (ja)
Other versions
JP2000327579A (en
Inventor
基博 中島
Original Assignee
基博 中島
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 基博 中島 filed Critical 基博 中島
Priority to JP11115335A priority Critical patent/JP3117964B2/en
Publication of JP2000327579A publication Critical patent/JP2000327579A/en
Application granted granted Critical
Publication of JP3117964B2 publication Critical patent/JP3117964B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】この発明は腫瘍細胞由来物質
から霊菌により合成される抗腫瘍性物質に関するもので
ある。
TECHNICAL FIELD The present invention relates to a substance derived from a tumor cell.
Related to antitumor substances synthesized by germs
is there.

【0002】[0002]

【従来の技術】従来の抗肺瘍性物質は化学合成されたも
のか、非腫瘍生物からの抽出物である。腫瘍及び腫瘍産
生物を菌により分解せしめ、抗腫瘍性物質を合成した報
告は未だない。
2. Description of the Related Art Conventional anti-pulmonary substances are chemically synthesized.
Or an extract from a non-tumor organism. Tumor and tumor production
Report on the synthesis of antitumor substances by decomposing living organisms with fungi
There is no notice yet.

【0003】[0003]

【発明が解決しようとする課題】本発明者は研究の結
果、腫瘍細胞由来の物質(抗腫瘍物質=腫瘍細胞変性物
質合成の基本となる物質)を霊菌により分解し、抗腫瘍
性物質=腫瘍細胞変性物質 を合成し、この物質の分子構
成を明らかにした。
SUMMARY OF THE INVENTION The present inventor has concluded the research.
As a result, a substance derived from a tumor cell (antitumor substance = tumor cell denatured substance)
Is degraded by a bacterium to produce antitumor
Synthetic substance = Synthesizes a tumor cell degenerating substance, and the molecular structure of this substance
Clarified.

【0004】本発明はこの研究結果を利用するものであ
り、その課題は、腫瘍細胞由来の物質から霊菌の働きに
より合成される腫瘍細胞に変性をもたらす抗腫瘍性物質
を提供することにある。
[0004] The present invention utilizes this research result.
The challenge is to convert the substance derived from tumor cells
Antitumor substance that causes degeneration in tumor cells synthesized more
Is to provide.

【0005】[0005]

【課題を解決するための手段】請求項1の発明は、腫瘍
細胞由来の物質から霊菌により合成された下記構造式よ
りなる抗腫瘍性物質であることを特徴とする。
According to the first aspect of the present invention, a tumor
According to the following structural formula synthesized by cell spirits from cell-derived substances
Characterized in that it is an antitumor substance.

【0006】構造式 [0006] Structural formula

【化1】 Embedded image

【0007】[0007]

【実施例】この実施例ではDDY系マウスとエールリッ
ヒ腫瘍細胞を用いた。腫瘍細胞由来の物質から(抗腫瘍
性物質=腫瘍細胞変性物質合成の基本となる物質)の
出を以下の順に従って処理した。 (1)腫瘍細胞培養腹水(500mlを1単位とした)
を加熱処理(腫瘍細胞に熱変性をもたらす。)したのち
にエチルアルコール80%濃度にて凝固、抽出を行い、
東洋ろ紙No.2でろ過する。 (2)アルコールを蒸発除去したのちに析出した非水溶
性物質をろ紙No.2でろ過除去する。 (3)アルコールの完全除去を確認してからアセトンを
加え、アセトン80%濃度で処理をしてアセトン凝固物
質を東洋ろ紙No.2でろ過する。 (4)アセトンを蒸発除去後、クロロホルムを加えよく
振盪する。クロロホルム層を分別漏斗にて分離し、クロ
ロホルムを蒸発除去後、蒸留水を加え、水溶液を作成す
る。 (5)この水溶液にエーテルを加えてよく振盪後、水層
を分離し濃縮する。 (6)この濃縮液をペーパークロマト法(降下法、展開
溶液:ブタノール:氷酢酸:水=4:1:2)で分離、
Rf=0.25−0.3の範囲にニンヒドリン反応陽性
物質を得る。(これが腫瘍細胞由来の抗腫瘍性物質=腫
瘍細胞変性物質合成の基本となる物質である。) (7)抗腫瘍性物質の確認方法は、前(6)項で確認分
離抽出した物質を含むNaCl 0.5%、ブドウ糖1
%、ATP40mg、pH6.8〜7.0の培養液を作
製し、霊菌(細菌)を36.5℃で5日間培養する。
(培養5日間の理由:ブドウ糖を霊菌が分解しpHが低
下し分解・合成を停止するには培養開始後5日目からで
ある。)培養終了後、減菌ろ過を行い、その後、エチル
アルコール80%濃度で処理、ろ過、アルコールを蒸発
除去後する。しかる後、アセトン80%濃度で処理、ろ
過、アセトンを蒸発除去後、クロロホルムを加え振盪
し、クロロホルム層をし分離する。分離たクロロホルム
層はクロロホルムを蒸発除去後、蒸留水を加えて水溶液
を作る。この水溶液にはエーテルを加えよく振盪後、こ
の水層を分離し濃縮して濃縮物とする。濃縮物は前記の
ペーパークロマト法で分離し、Rf=0.13−0.1
7の範囲にニンヒドリン反応陽性物質(抗腫瘍性物質=
腫瘍細胞変性物質)を得る。この分画を抽出し、以下に
示す測定条件において高速液体クロマト法にて精製し、
約2mlに濃縮した。 この濃縮物は腫瘍細胞(エールリッヒ腫瘍細胞)を腹膣
内に移植したマウスの皮下又は腹膣内に、腫瘍細胞腹膣
内移植3日目から、3日に1回の割合で0.5mlずつ
投与した。腫瘍細胞移植後10日又は12日目に腹水を
採取しギムザ染色法にて腫瘍細胞の変性を確認した。
の結果は、図1、図2の顕微鏡写真に示すように、腫瘍
細胞の変性をもたらしたその細胞質が漏出していること
認められた。又その核の分解も観察された。此処に提
示した抗腫瘍性物質(腫瘍細胞変性物質)の作用機序は
腫瘍細胞の変性によって娘細胞を分離後の腫瘍細胞壁の
修復が障害されて腫瘍細胞の分解にいたると考えられ
る。 (8)合成された抗腫瘍性物質の分子量、分子構造は、
NMRとMSの測定構造解析を行い、以下の結果を得
た。この構造は窒素を含まないが、ペーパークロマト法
のオーダーでみられたニンヒドリン発色は共存したホル
ムアミド(NHCHO)と考えられる。尚、質量分析
(MS)の結果からこの構造式は分子量196と認めら
れる。
EXAMPLES In this example, DDY mice and Ehrlich tumor cells were used. Extracted from material from tumor cells (anti-tumor substance = underlying material of tumor cells modified material synthesis)
Discharge was processed in the following order. (1) Tumor cell culture ascites (500 ml was defined as 1 unit)
After heat treatment (causing heat denaturation of tumor cells), coagulation and extraction were performed at 80% ethyl alcohol concentration.
Toyo filter paper No. Filter through 2. (2) The water-insoluble substance precipitated after the alcohol was removed by evaporation was used as filter paper No. Filter off at 2. (3) After confirming complete removal of the alcohol, acetone was added, and the mixture was treated with acetone at a concentration of 80%. Filter through 2. (4) After removing acetone by evaporation, add chloroform and shake well. The chloroform layer is separated by a separation funnel, chloroform is removed by evaporation, and distilled water is added to prepare an aqueous solution. (5) After adding ether to the aqueous solution and shaking well, the aqueous layer is separated and concentrated. (6) Separate the concentrated solution by a paper chromatography method (descent method, developing solution: butanol: glacial acetic acid: water = 4: 1: 2),
A ninhydrin reaction-positive substance is obtained in the range of Rf = 0.25-0.3. (This is an antitumor substance derived from a tumor cell = a substance that is the basis of the synthesis of a tumor cell degenerating substance.) (7) The method of confirming an antitumor substance includes the substance identified and extracted in the above (6). NaCl 0.5%, glucose 1
%, 40 mg of ATP, pH 6.8-7.0, and cultivation of a bacterium (Bacteria) at 36.5 ° C. for 5 days.
(Reason for 5 days of cultivation: From the 5th day after the start of cultivation, glucose is decomposed by spirit bacteria to lower the pH and the decomposition / synthesis is stopped.) After cultivation, sterile filtration is performed, and then ethyl is added. After treatment with alcohol at a concentration of 80%, filtration and removal of the alcohol by evaporation . Thereafter, the mixture is treated with acetone at a concentration of 80%, filtered, and the acetone is removed by evaporation. Then, chloroform is added and the mixture is shaken to separate and separate the chloroform layer . Chloroform isolated
After evaporating off chloroform, distilled water is added to the layer to form an aqueous solution. Ether is added to this aqueous solution, and after shaking well, the aqueous layer is separated and concentrated to obtain a concentrate. The concentrate was separated by the above-mentioned paper chromatography method, and Rf = 0.13-0.1
Ninhydrin reaction positive substances (anti-tumor substances =
Tumor cytopathic material). Extract this fraction, below
Purified by high performance liquid chromatography under the indicated measurement conditions ,
It was concentrated to about 2 ml . The concentrate in tumor cells (Ehrlich tumor cells) transplanted subcutaneously or intra-abdominal vagina mouse abdominal vagina, from tumor cells abdominal vaginal implantation day 3, each 0.5ml once every 3 days was administered. On day 10 or day 12 after tumor cell transplantation, ascites was collected and degeneration of tumor cells was confirmed by Giemsa staining. This
As shown in the photomicrographs of FIGS. 1 and 2, it was confirmed that the cytoplasm that caused the degeneration of the tumor cells was leaked . Decomposition of the nucleus was also observed. The mechanism of action of the antitumor substance (tumor cell degenerating substance) presented here is thought to be due to degeneration of the tumor cells, which impairs the repair of the tumor cell wall after separation of daughter cells, leading to degradation of the tumor cells. (8) The molecular weight and molecular structure of the synthesized antitumor substance are as follows:
The structure was analyzed by NMR and MS, and the following results were obtained. Although this structure does not contain nitrogen, the ninhydrin coloring observed on the order of the paper chromatography method is considered to be formamide (NH 2 CHO) coexisting. In addition, this structural formula is recognized as a molecular weight of 196 from the result of mass spectrometry (MS).

【0008】構造式[0008] Structural formula

【化2】 Embedded image

【0009】[0009]

【発明の効果】本発明によれば、腫瘍細胞由来の物質か
ら霊菌により合成した前記構造式の抗腫瘍性物質が提供
される。
According to the present invention, a substance derived from a tumor cell
Provided an anti-tumor substance of the above structural formula synthesized by psychiatric fungi
Is done.

【図面の簡単な説明】[Brief description of the drawings]

【図1】変性した腫瘍細胞の顕微鏡写真(写し)を示す
図である。
FIG. 1 is a photomicrograph (copy) of a degenerated tumor cell.

【図2】核の分解した細胞の顕微鏡写真(写し)を示す
図である。
FIG. 2 is a photomicrograph (copy) of nucleated cells.

Claims (1)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】 腫瘍細胞由来の物質から霊菌により合成
された下記構造式よりなる抗腫瘍性物質。 構造式 【化1】
1. Synthesizing a substance derived from a tumor cell by a psychiatric fungus
An antitumor substance having the following structural formula: Structural formula [ Formula 1]
JP11115335A 1999-03-17 1999-03-17 Antitumor substance Expired - Lifetime JP3117964B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP11115335A JP3117964B2 (en) 1999-03-17 1999-03-17 Antitumor substance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11115335A JP3117964B2 (en) 1999-03-17 1999-03-17 Antitumor substance

Publications (2)

Publication Number Publication Date
JP2000327579A JP2000327579A (en) 2000-11-28
JP3117964B2 true JP3117964B2 (en) 2000-12-18

Family

ID=14660014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11115335A Expired - Lifetime JP3117964B2 (en) 1999-03-17 1999-03-17 Antitumor substance

Country Status (1)

Country Link
JP (1) JP3117964B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4343153B2 (en) 2005-05-12 2009-10-14 基博 中島 Method for producing antitumor composition

Also Published As

Publication number Publication date
JP2000327579A (en) 2000-11-28

Similar Documents

Publication Publication Date Title
JP5172851B2 (en) Method for producing chlorophyll a and chlorin e6
CN104367600B (en) Application of Antrodia camphorata extract in preparing medicine for regulating Th17 cells or treating diseases related to Th17 cell regulation
JP3117964B2 (en) Antitumor substance
DE3109335A1 (en) THE NEW, PHYSIOLOGICALLY EFFECTIVE SUBSTANCE EBELACTONE AND METHOD FOR THE PRODUCTION THEREOF
TWI241344B (en) Processes for producing an antrodia camphorata culture having pharmacological activity, processes for obtaining a pharmacologically active composition from a culture of A camphorata, products produced thereby and pharmaceutical compositions of cancer...
US4952399A (en) Pharmaceutical composition which inhibits the growth of a tumor
WO1998056755A1 (en) Physiologically active substances tkr2449, process for producing the same, and microorganism
US20020119937A1 (en) Fermentation and purification of migrastatin and analog
CN112843026B (en) Application of diphenyl ether compound in preparation of acetylcholinesterase inhibitor or medicament for treating Alzheimer disease
RU2005478C1 (en) Method for production of concentrated sapropel
KR100559263B1 (en) A method of preparing ergosterol epoxide and physiologically acceptable salts thereof from Lentinus edodes
JPH0622781A (en) Production of dauricine
EP0295273A1 (en) Method of isolating vinblastine
SU1586520A3 (en) Method of producing n-nitroso-n-(beta-chloroethylcarbamoylpeptides)) or their salts
JP3088680B2 (en) Synthetic method of antitumor substance by intestinal bacteria and ray bacteria
JP2757342B2 (en) Isoindolinone derivative, cervical cancer cell killing agent containing the same as active ingredient, and method for producing the same
KR0136447B1 (en) Novel activity polyozellus having anti-cancer activity produced by a strain of polyozellus multiplex and a process for producing them
JP3673304B2 (en) New wound healing material
CN1580043A (en) Anti malignant tumour southern radix bupleuri extract preparing method
JPH0656861A (en) Separation of antitumor substance from crude drug
CN117323352A (en) Cordyceps sinensis extract with podocyte protection activity and preparation method and application thereof
JP3673305B2 (en) New wound healing material
JPH05271267A (en) Fr901459 substance, and its production and use
CN1055932A (en) A kind of method of the compound (GMD1630) by garcinia black nightshade plant (G.M.D.) resin purification purifying solubilized cell
KR840001510B1 (en) Process for preparing extract from plant of genus epimedium s.p.

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313532

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091006

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101006

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101006

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111006

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111006

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121006

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131006

Year of fee payment: 13

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term